Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

Major manufacturing investment to support API production for tirzepatide

6
SHARES

Eli Lilly and Company has committed the largest US investment in synthetic medicine active pharmaceutical ingredient (API) manufacturing.

tirzepatide API manufacturing

A new $5.3 billion investment for Eli Lilly and Company’s manufacturing site in Lebanon, Indiana, US, increases the firm’s total investment there from $3.7 billion to $9 billion. This expansion will expand manufacturing capacity of active pharmaceutical ingredients (APIs) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection. These treatments are indicated for obesity and type 2 diabetes.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

This new $5.3 billion investment tops the largest manufacturing investment in [Eli Lilly’s] history”

This new $5.3 billion investment “tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in US history,” commented David Ricks, Eli Lilly’s chair and CEO. “This multi-site campus will make our latest medicines, including Zepbound and Mounjaro, support pipeline growth and leverage the latest technology and automation for maximum efficiency, safety and quality control.”

Benefits of the tirzepatide API investment

Supported through this new investment to expand API capacity for tirzepatide, Eli Lilly stated that anticipates an additional 200 full-time jobs including engineers, scientists, operating personnel and lab technicians will be added at the Lebanon, Indiana site.  

Furthermore, the company estimates that a total of 900 people will be employed full-time at the facility when it is fully operational.

A learning and training centre will be part of the larger Limitless Exploration Advanced Pace (LEAP) Research and Innovation District industrial development, Eli Lilly confirmed.

Eli Lilly anticipates that medicine production at the Lebanon site will begin near the end of 2026.

Manufacturing for the future

The company highlighted that it has committed over $16 billion to develop new manufacturing sites in the US and Europe since 2020, including in a biologic facility in Limerick, Ireland.

Eli Lilly added that it has invested more than $18 billion to update its existing US manufacturing facilities. These include a $1.2 billion investment at its Indianapolis site and an injectable manufacturing facility in Wisconsin. The latter facility was recently acquired from Nexus Pharmaceuticals.

Eli Lilly reveals plans for new high-tech parenteral manufacturing site

Share via
Share via